Related Experiment Video

Updated: Jun 11, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus

E Aragon1, Y H Chan, K H Ng

  • 1Shaw-NKF-NUH Children's Kidney Centre, University Children's Medical Institute, National University Health System, Singapore.

Lupus
|June 29, 2010
PubMed

Insights

A new mycophenolate and cyclosporine (MMF-CSA) protocol effectively treats severe proliferative lupus nephritis (LN) in children. This MMF-CSA regimen significantly improves clinical and serological markers, leading to high rates of renal remission.

Area of Science:

  • Pediatric Nephrology
  • Immunology
  • Rheumatology

Background:

  • Severe proliferative lupus nephritis (LN) in children presents significant challenges.
  • Current induction protocols require optimization for improved outcomes.

Purpose of the Study:

  • To evaluate the efficacy of a novel mycophenolate mofetil and cyclosporine (MMF-CSA) induction protocol for severe proliferative lupus nephritis in pediatric patients.
  • To assess clinical and laboratory improvements at 6 and 12 months post-induction.

Main Methods:

  • Retrospective study of 16 children with lupus nephritis (WHO class III and IV).
  • Patients received a combination MMF-CSA induction protocol.
  • Clinical and laboratory parameters including SLEDAI, renal function, proteinuria, and serological markers were compared pre-induction, at 6 months, and 12 months.

Main Results:

  • Significant improvements observed in SLEDAI, C3, C4 levels, and urine protein (p < 0.05).
  • Anti-dsDNA titres decreased in 73% of patients by 6 and 12 months (p < 0.05).
  • Complete renal remission achieved in 43.8% at 6 months and 75% at 12 months; partial remission in all remaining patients.

Conclusions:

  • The MMF-CSA combination protocol is an effective induction therapy for severe proliferative pediatric LN.
  • This regimen leads to significant clinical and serological improvements with minimal adverse effects.
  • MMF-CSA offers a promising therapeutic alternative for managing pediatric lupus nephritis.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...